

University of Miami

Gustavo L. Fernández-Castro MD, MBA.

Curriculum Vitae

1. **DATE:** September 16th, 2014

PERSONAL:

2. **Name:** Gustavo L. Fernández-Castro.
MD, MBA, SSBB.

3. **Office Phone:** (305) 243-6608

4. **Current Academic Rank:** Assistant Professor of Hematology-
Oncology, Department of Medicine.

5. **Primary Department:** Medicine

6. **Secondary or Joint
Appointment:** N/A

7. **Citizenship:** United States of America

8. **Visa Type:** N/A

HIGHER EDUCATION:

11. **Institutional:**

- University of Miami Business School of Medicine, Miami, Florida; Executive MBA in Health Sector Management and Policy; January 2011 – December 2012
- University of Miami Sylvester Comprehensive Cancer Center /Jackson Memorial Hospital, Miami, Florida; Hematology/Oncology Fellowship, July 1998 - June 2001
- Fred Hutchinson Cancer Research Center, Bone Marrow Transplant Unit; visiting Physician, Seattle, Washington, March 2000

- University of Miami /Jackson Memorial Hospital, Miami, Florida, Residency in Internal Medicine, Position obtained through the Latin American Program, July 1995 - June 1998
- University of Miami/Jackson Memorial Hospital, Miami, Florida, Visiting physician for Latin American Program; Elective rotations in the subspecialties of Internal Medicine. August 1994- December 1994
- Lipid Outpatient Clinic; December 1993- July 1994. Hospital De Clinicas. Montevideo-Uruguay

12. Non-Institutional: N/A

13. Certification, licensure:

- Six Sigma Black Belt. University of Miami. September 2014.
- Six Sigma Green Belt. University of Miami. September 2013.
- The American Board of Medicine, Certification in Oncology; 2001; recertification: 2012.
- The American Board of Medicine, Certification in Hematology; 2001; recertification: 2012.
- The American Board of Medicine, Certification in Internal Medicine; 1998; recertification: 2009.
- Florida Board of Medicine; Medical License. 1997.
- Educational Commission for Foreign Medical Graduates Certification. 1994.
- Medical License; Uruguay; 1993.

EXPERIENCE:

14. Academic:

- University of Miami, Miami, Florida; Department of Medicine, Division of Hematology-Oncology, Miami, Florida; Assistant Professor; August 2008 – Present.

- Cleveland Clinic Foundation, Division of Hematology-Oncology, Weston, Florida; Attending Physician; June 2007-July 2008.
- Veterans Administration Hospital, Division of Hematology-Oncology, West Palm Beach, Florida; Attending Physician; September 2003 –June 2007.
- University of Miami, Miami, Florida; Department of Medicine, Division of Hematology-Oncology, Miami, Florida; Assistant Professor; July 2001-June 2004.

14a Hospital Appointments:

- **Medical Director of the Hematology/Oncology Clinics and Comprehensive Treatment Unit at Sylvester Cancer Center.** May 2013 to present.
- **Associate Director for Clinical Affairs for the Division of Hematology/Oncology. Sylvester Cancer Center.** May 2013 to present.
- **Associate Director for Performance Initiatives for UM Sylvester Cancer Center. Quality Department.** May 2013 to present.
- **Director of Hematology-Oncology at University of Miami Hospital.** August 2008 to present.
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida; August 2008 to present.
- University of Miami Hospital, University of Miami, Miami, Florida; August 2008 to present.
- Jackson Memorial Hospital; Miami, Florida; August 2008 to present.
- Cleveland Clinic Florida, Weston Florida; June 2007-July 2008.
- Veterans Administration Medical Center, West Palm Beach, Florida; September 2003-June 2007.
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida; September 1996-June 2003.

- Jackson Memorial Hospital; Miami, Florida; September 1996-June 2003.

15. Non-Academic: N/A

16. Military: N/A

PUBLICATIONS:

17. **Books:N/A**

18. **Juried or referenced journal articles or exhibitions: (* Corresponding Author)**

In Press or Published: (Total: 11)

Gjolaj L, Gari G, Olier-Pino, A, Garcia J, **Fernandez G**. Decreasing Laboratory Turnaround Time and Patient Wait Time by Implementing Process Improvement Methodologies in an Outpatient Oncology Infusion Unit. *Journal of Oncology Practice (JOP)* (Accepted for publication) (In press). 2014.

Manzano A, Nose V, **Fernandez-Castro G**, Ayala A. Recurrent Primary Leiomyosarcoma: A complete literature review and presentation of a rare adrenal tumor. *Endocrine Practice Journal* (Accepted for publication) (In press). 2014.

Mahmoud O, Dosch A , Kwon D, Pitcher JD, Conway S, Benedetto P, **Fernandez G**, Trent J, Temple HT, Wolfson AH. The impact of Perioperative Chemotherapy Timing in Conjunction with Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome. *Am J Clinic Oncol*. 2014 May 29. [Epub ahead of print].

Fabregas JC, Loaiza-Bonilla A, Talebi TN, Warsh S, **Fernandez G**, Raez LE, Santos ES. Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer. *Expert Rev Anticancer Ther*. 2013 Sep, 13(9): 1065-72

Ransford G, Ayyathurai R, **Fernandez-Castro G**, Ciancio G. Surgical management of a neuroendocrine tumor of the inferior vena cava. *J Vasc Surg*. 2013 Aug; 58(2): 496-9

Thompson S, Gomez-Fernandez C, Mejias A, Cioffi-Lavina M, Chapman-Fredricks J, **Fernandez-Castro G**, Jorda M*. Distinction of High-Grade Neuroendocrine Carcinoma/Small Cell Carcinoma from Conventional Urothelial Carcinoma of Urinary Bladder: An Immunohistochemical Approach. *Appl Immunohistochem Mol Morphol*. 2011 Oct; 19(5):395-9.

Fernandez-Castro G*. Side Effects and Complications of Androgen Deprivation in Prostate Cancer Patients. *The Open Prostate Cancer Journal*, 2010, 3, 29-38.

Talebi T, **Fernandez-Castro G**, Montero AJ, Stefanovic A, Lian E. A Case of Severe Thrombotic Thrombocytopenic Purpura With Concomitant Legionella Pneumonia: Review of Pathogenesis and Treatment. *Am J Ther*. 2011 Sep;18(5):e180-5.

Jorda M, Gomez-Fernandez C, Garcia M, Mousavi F, Walker G, Mejias A, **Fernandez-Castro G**, Ganjei-Azar P. p63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples: implications in treatment selection. *Cancer*. 2009 Feb 25;117 (1):46-50.

Jorda M, Ghorab Z, **Fernandez G**, Nassiri M, Hanly A. Low nuclear proliferative activity is associated with Non-metastatic islet cell tumors. Semiquantitative evaluation of 39 cases. *Arch Pathol Lab Med* 127: 196-199, 2003.

Jorda M, Morales A, Ghorab Z, **Fernandez G**, Nadji M, Block N. Her2 Expression in Prostate Cancer. A Comparison with Mammary Carcinoma. *Journal of Urology . J Urol*. 2002 Oct; 168(4 Pt 1):1412-4.

Other works, publications and abstracts (Total: 8):

Fernandez-Castro G, Vaughn D, Schally A, Koru-Sengul, T, Merchan J, Flores A, Jorda M, Benedetto P, Singal R, Block N. Phase 1 trial of zoletarelin doxorubicin (Zop-Dox) in advanced unresectable or metastatic urothelial carcinoma (UC) patients who failed platinum-base chemotherapy. *J Clin Oncol* 32, 2014 (suppl; abstr e 15517)

Fernandez-Castro G, Schally A, Koru-Sengul T, Jorda M, Merchan J, Flores A, Block N, Manoharan M, Engel J. Long-term response in a patient with urothelial cancer (UC) treated with AEZS-108. *J Clin Oncol* 31, 2013 (suppl; abstr e 15596)

Rick FG, Szalontay L, **Fernandez-Castro G**, Block NL, Keller G, Szepeshazi K, Schally AV. Effective treatment of urinary bladder cancers by targeted cytotoxic LHRH analog AEZS-108 (AN-152): a preclinical report. *J Urol*. 187(4S) e432-3, 2012.

Yasir S, Umar S, **Fernandez-Castro G**, Block N, Schally A, Cote R, Jorda M. Immunohistochemical Expression of LHRHR in Muscle-Invasive Urothelial Carcinoma of Urinary Bladder: A Potential Predictive Marker for Targeted Cytotoxic LHRH Hybrid Analogs. *Arch Pathol Lab Med*, 136: pp 1040, # 37, 2012

Paluru S, Yasir S, Umar S, Ciancio G, **Fernandez-Castro G**, Block N, Schally A, Cote R, Jorda M. LHRHR Is Diffusely Expressed In Two-Thirds Of Renal Cell Carcinomas By Immunohistochemistry: A Potential Predictive Marker For Targeted Cytotoxic LHRH Hybrid Analogs. *Arch Pathol Lab Med*, 136: pp 1043, #48, 2012

Zhang Y, Rodriguez S, Gomez-Fernandez C, Garcia M, Ganjei-Azar P, **Fernandez-Castro G**, Jorda M. Immunocytochemical Detection of HER2 in Urine Cytology in Previously Papanicolaou-Stained Slides.is Comparable to Correspondent Urothelial

Carcinoma Tissue Samples. Modern Pathology 23A, #457, 2012.

G Lopez, Negret L, **Fernandez-Castro G**, Jorda M, Hurley J, Powell J, Silva O. Breast Cancer and neuroendocrine tumor can pose a diagnostic challenge. ASCO proceedings. # 868, 92, 2004

Fernandez-Castro G, W. Mnaymneh, H.T. Temple, L. Gandhur-Mnaymneh, F Moffat, A. Wolfson , P. Benedetto. Neoadjuvant Chemotherapy for Adult, Nonmetastatic, Intermediate (G2) or High Grade (G3) Appendicular Soft Tissue Sarcoma. ASCO proceedings # 2943, 281B, 2002.

Scientific Poster Presentations (Total: 8)

Malmoud O, Wolfon A, Dean EM, Cohen D, Walker GR, Pitcher JD, Conway S, Benedetto P, **Fernandez-Castro G**, Temple T. A ten-year single institution experience with adjuvant external beam radiation therapy for extremity soft tissue sarcoma. Connective tissue oncology Society, 17th Annual meeting, Prague, Czech Republic, November 2012.

Negret L, Lopes G, **Fernandez-Castro G**, Jorda M, Hurley J, Powell J, Silva O. Metastatic Breast Carcinoma with Neuroendocrine Features: Its Recognition and Impact in Patient Management. 2nd Interamerican Conference of Breast Cancer in Cancun Mexico, July 2004.

Silva O, **Fernandez-Castro G**, Negret L, Lopes G, Jorda M, Hurley J, Powell J. Breast Cancer and Neuroendocrine Tumor: A Complex Diagnostic Challenge. Annual UM/Sylvester Cancer Research Poster Session, June 2004.

Fernandez-Castro G, Mnaymneh W, Temple HT, Mollabashy A, Gandhur-Mnaymneh L, Jorda M, Moffat F, Wolfson A, Benedetto P. Neoadjuvant chemotherapy for adult, non-metastatic intermediate (g2) or high grade (g3) appendicular soft tissue sarcoma. VIIth Annual Joint Cancer Conference of the Florida Universities, Orlando, Florida, February 2003.

Fernandez-Castro G, Benedetto P. Clinical Patterns of Poor Outcome In-Patients with Primary Mediastinal Nonseminomatous Germ Cell Tumors. 6^o Annual Joint Cancer Conference of the Florida Universities. Orlando, Florida, January 2002.

Kuker RA, **Fernandez-Castro G**, Block N, Correa J, Torrente J, Serafini AN. Tumoricidal effects of SM-153 EDTMP as measured by PSA levels. Sylvester Comprehensive Cancer Center Poster Session/Competition, Miami, Florida, June 2002

Fernandez-Castro G, Benedetto P. Clinical Patterns of Poor Outcome In-Patients with Primary Mediastinal Nonseminomatous Germ Cell Tumors. 6^o Annual Joint Cancer Conference of the Florida Universities. Orlando, Florida, January 2002. Abstract # 4

Jorda M, Ghorab Z, Block N, **Fernandez-Castro G**, Nassiri M, Nadji M. High Expression Of Her2 Is uncommon In prostatic adenocarcinoma. Annual Poster Presentation, Sylvester Comprehensive Cancer Center, Miami, Florida, June 2001.

19. **PROFESSIONAL:**

Research:

A phase I/II trial of an-152 [AEZS-108] in locally advanced unresectable or metastatic LHRH positive urothelial carcinoma patients who failed platinum based chemotherapy. 7/6/2010- 6/2/2014

Phase II study of skin toxicity dose of IRESSA® (GEFITINIB) as monotherapy in recurrent and/or metastatic squamous cell carcinoma of the head and neck". 12/1/2005-10/4/2013

Multicenter randomized phase ii study of erlotinib, cisplatin and radiotherapy versus cisplatin and radiotherapy in patients with stage III and IV squamous cell carcinoma of the head and neck. 9/28/2006-10/1/2013

Sorafenib and cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck:: a phase II trial. 12/15/2008-10/30/2013

ECOG1302, phase III, randomized, placebo-controlled, trial of docetaxel vs. Docetaxel plus ZD 1839 (iressa, gefitinib) in performance status 2 or previously treated patients with recurrent or metastatic head and neck cancer. 6/16/2005- 4/8/2013.

A phase iii trial of docetaxel based induction chemotherapy in patients with N2/N3 locally advanced head and neck cancer. 4/20/2005/9/2014

A randomized, phase 3 study of dose escalation versus no dose escalation of imatinib in metastatic GIST patients with imatinib trough levels less than 1100 nanograms/ml. 4/20/2005-1/9/2014

Departmental administrative and committee responsibilities:

Six Sigma Projects: Portfolio:

- Reduction of Medical Necessity Accounts at Sylvester

Comprehensive Cancer (SCCC) / University Miami Hospital & Clinic (UMHC). 2014. Ongoing

- Reducing Patient Wait Time for chemotherapy. Ongoing. 2014
- Reduction of No Authorization Denials Charges at Sylvester Comprehensive Cancer (SCCC) / University Miami Hospital & Clinic (UMHC). 2013-2014.
- CTU Process Improvement Project. 2013-2014.

2013 Medical Director of the Hematology/Oncology Clinics and Comprehensive Therapy Unit at Sylvester Cancer Center.

Associate Director for Clinical Affairs for the Division of Hematology/Oncology. Sylvester Cancer Center.

Associate Director for Performance Initiatives for UM Sylvester Cancer Center. Quality Department.

2008 Chief of Hematology-Oncology at University Miami Hospital

2003 Chairman of Cancer Committee. Veterans Administration Hospital West Palm Beach.

2002 to August 2003. Medication Occurrence Committee Review Sylvester Cancer Center. Miami, Florida

2002 to August 2003. Pharmacology Committee Review Sylvester Cancer. Miami, Florida

Professional and Honorary Organizations:

Florida Sterling Board of Examiners. On Training. Due 2015

American Cancer Society of Clinical Oncology. 1999.

20. Honors and Awards:

- Celebration of Service Award in the under 150-bed category for Innovation of the Year in Patient Care. Florida Hospital Association (FHA). October 2014. Orland FL. (Team CTU award).
- First Prize in the 2014 Annual Florida Sterling Conference Team Showcase competition. May 2014. Orlando Fl. (Team CTU award). The Sterling recognizes organizational teams that have demonstrated outstanding performance improvement or problem-solving achievements. "Team CTU Miami" won the statewide competition over five other finalist for a project entitled: " Systematically Decreasing Wait Time in an Outpatient Oncology Treatment Unit"
- Valedictorian; University of Miami Business School of Medicine, Miami, Florida; Executive MBA in Health Sector Management and Policy; January 2011- December 2012
- Doctor of the year, Veterans Administration Hospital, West Palm Beach, Florida, 2003.
- Valedictorian; Summa cum Laude, M.D. degree: Universidad de la Republica, Montevideo, Uruguay, 1993